Headquartered in Bridgewater, NJ Fiscal year ends December NASDAQ: INSM insmed.com
Insmed Incorporated is a global biopharmaceutical company focused on delivering therapies for patients facing serious diseases, organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. Its commercial portfolio includes BRINSUPRI (brensocatib), a once-daily oral DPP1 inhibitor approved in the U.S. and Europe for non-cystic fibrosis bronchiectasis (NCFB), and ARIKAYCE (amikacin liposome inhalation suspension), a once-daily inhaled antibiotic approved in the U.S., Europe, and Japan for refractory Mycobacterium avium complex (MAC) lung disease. The company's clinical pipeline is anchored by TPIP (treprostinil palmitil inhalation powder), a potentially differentiated once-daily inhaled prostanoid in Phase 3 development across four pulmonary indications (PAH, PH-ILD, PPF, and IPF). Earlier-stage programs include INS1148 (anti-SCF248 monoclonal antibody for fibrotic lung diseases), INS1033 (second-generation DPP1 inhibitor for rheumatoid arthritis and other inflammatory conditions), and two AAV9 gene therapies — INS1201 for Duchenne muscular dystrophy and INS1202 for ALS. Insmed's research engine spans gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue modalities. Updated
Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find…
Stanley Druckenmiller is skipping the mega-cap tech herd and loading up on a Mexican discount grocer, an Argentine shale producer, and a biotech that Wall Street just handed a 38% discount despite…
Billionaire investor Stanley Druckenmiller is known for making bold moves when conviction is high, and his latest portfolio changes suggest he sees a major opportunity developing in one corner of the market.…
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on…
Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM | INSM Price Prediction) and its lung disease franchise: Japan has more patients with MAC lung disease than the…
Pre-Market Stock Futures: Futures are trading lower as we prepare to wrap up a rollercoaster week marked by huge market swings. Still, ultimately, President Trump’s TACO (Trump Always Chickens Out) move on…
Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning. He has been piling into Natera (NASDAQ:NTRA | NTRA Price Prediction),…
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing. He’s now piling into Natera (NASDAQ:NTRA | NTRA Price…
Thursday's top analyst upgrades and downgrades included Alphabet, Eli Lilly, Etsy, Microsoft, Mosaic, NetApp, Omega Healthcare Investors, RTX, Sherwin-Williams, Spotify Technology, Walt Disney and WW International.
Thursday's top analyst upgrades and downgrades included Airbnb, Applied Materials, AutoZone, BorgWarner, Carvana, Dominion Energy, EQT, MongoDB, NRG Energy, PagSeguro Digital, Southwestern Energy, Stitch Fix, StoneCo and TripAdvisor.
Wednesday's top analyst upgrades and downgrades included Albemarle, Camping World, eBay, EOG Resources, Etsy, Global Payments, IMAX, JPMorgan Chase, MetLife, Otis Worldwide, Salesforce, Wayfair and Zillow.
Thursday's top analyst upgrades and downgrades included Alphabet, Allstate, Antero Midstream, Archer Daniels Midland, Capital One Financial, Chipotle Mexican Grill, Corning, Microsoft, PepsiCo, QuantumScape, Range Resources, Spotify Technology, Texas Instruments, Visa and…
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic…
Insmed Incorporated is a global biopharmaceutical company focused on delivering therapies for patients facing serious diseases, organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare.
The Wall Street consensus 12-month price target for INSM is $197.74. INSM price prediction →
